Grants / Department of Defense / Defense Health Agency Contracting Activity - DHACA

W81XWH-22-TBDRP-TDRA: DoD Tick-Borne Disease, Therapeutic/Diagnostic Research Award

Closed Closed August 25, 2022 Opportunity W81XWH-22-TBDRP-TDRA ☆ Save

This grant is closed. A newer notice from the same program is open now: DoW Breast Cancer, Clinical Research Extension Award (HT942526BCRPCREA2). Status: Closes November 18, 2026 (11 days left). It is in our archive of Defense Health Agency Contracting Activity - DHACA notices from 2022.

• Total funding$4.2 million
• Expected awards4
• Cost sharingNot required
• Funding typeCooperative Agreement, Grant

Key dates

Who can apply

This opportunity was open to any type of organization.

• Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

More grants for nonprofits, colleges and universities, state and local governments, tribes, small businesses, businesses, individuals.

Is this a realistic fit?

• Most of the program's money (59% over five years) went to colleges and universities.
• No cost sharing or match is required.

What the grant funds

The FY22 TBDRP Therapeutic/Diagnostic Research Award is intended to support hypothesis-driven therapeutic and diagnostic development research. Projects submitted under a Treatment Focus Area should be therapeutic evaluation studies designed to promote new ideas aimed at drug or treatment discovery that are still in the early/preclinical stages of development. Projects submitted under a Diagnosis Focus Area should propose diagnostic approaches that will be readily integrated into clinical settings. All research projects should have a translational potential and aim to improve patient care and/or the quality of life for military Service Members, Veterans, and their beneficiaries, as well as the American public living with Lyme disease and/or other tick-borne diseases. The proposed studies are expected to be empirical in nature and product-driven. Applicants with limited tick-borne disease experience are strongly encouraged to collaborate with experienced tick-borne disease investigators. Applicants with substantial tick-borne disease experience are strongly encouraged to partner with experts in therapeutic and diagnostic assay development and transition, particularly those from the commercial sector. Examples of the types of research that may be supported by this award include, but are not limited to: • Evaluation, maturation, and/or down-selection of potential therapeutic candidates in vitro and/or in vivo • Design, development, and evaluation of proof-of-concept diagnostic assays or devices using in vitro or ex vivo samples • High throughput screening and confirmation of candidate therapeutics obtained from screening or by other means• Testing new therapeutic modalities (agents, delivery mechanisms) using established and accepted preclinical models • Preliminary studies on formulation, stability and safety prior to Good Manufacturing Practice production methods and evaluation in advanced preclinical studies • Investigational New Drug application-enabling studies leading to the development of pharmacologic agents, including compound characterization, absorption, distribution, metabolism, and excretion (ADME) studies, and dose/response and toxicology studies to demonstrate safety and efficacy in relevant model systems • Investigational Device Exemption application-enabling studies leading to the development of devices, including prototype development and device characterization, to demonstrate safety and efficacy using relevant model systems or samples •…

Category: Science and Technology and other Research and Development.

Applying now

This notice no longer takes applications. Apply under the newer notice, HT942526BCRPCREA2, which is open now.

The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.